BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29877250)

  • 1. [Treatment of NK/T-cell lymphoma: current situations and prospectives].
    Yamaguchi M
    Rinsho Ketsueki; 2018; 59(5):588-593. PubMed ID: 29877250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan.
    Yamaguchi M; Suzuki R; Oguchi M; Asano N; Amaki J; Akiba T; Maeda T; Itasaka S; Kubota N; Saito Y; Kobayashi Y; Itami J; Ueda K; Miyazaki K; Ii N; Tomita N; Sekiguchi N; Takizawa J; Saito B; Murayama T; Ando T; Wada H; Hyo R; Ejima Y; Hasegawa M; Katayama N
    J Clin Oncol; 2017 Jan; 35(1):32-39. PubMed ID: 28034070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy.
    Yamaguchi M; Suzuki R; Kim SJ; Ko YH; Oguchi M; Asano N; Miyazaki K; Terui Y; Kubota N; Maeda T; Kobayashi Y; Amaki J; Soejima T; Saito B; Shimoda E; Fukuhara N; Tsukamoto N; Shimada K; Choi I; Utsumi T; Ejima Y; Kim WS; Katayama N
    Cancer Sci; 2018 Jun; 109(6):2056-2062. PubMed ID: 29601137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extranodal NK/T-cell lymphoma: Updates in biology and management strategies.
    Yamaguchi M; Oguchi M; Suzuki R
    Best Pract Res Clin Haematol; 2018 Sep; 31(3):315-321. PubMed ID: 30213402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and future management of NK/T-cell lymphoma based on clinical trials.
    Yamaguchi M
    Int J Hematol; 2012 Nov; 96(5):562-71. PubMed ID: 23073619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current treatment approaches for NK/T-cell lymphoma.
    Yamaguchi M; Miyazaki K
    J Clin Exp Hematop; 2017 Dec; 57(3):98-108. PubMed ID: 28679966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NK/T Cell Lymphoma: Updates in Therapy.
    Suzuki R
    Curr Hematol Malig Rep; 2018 Feb; 13(1):7-12. PubMed ID: 29368155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type.
    Yamaguchi M; Suzuki R; Oguchi M
    Blood; 2018 Jun; 131(23):2528-2540. PubMed ID: 29602763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of new treatments for extranodal NK/T-cell lymphoma in Japan].
    Yamaguchi M
    Rinsho Ketsueki; 2015 Jun; 56(6):639-44. PubMed ID: 26256873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Features and Current Optimal Management of Natural Killer/T-Cell Lymphoma.
    Makita S; Tobinai K
    Hematol Oncol Clin North Am; 2017 Apr; 31(2):239-253. PubMed ID: 28340876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.
    Miyazaki K; Suzuki R; Oguchi M; Taguchi S; Amaki J; Maeda T; Kubota N; Maruyama D; Terui Y; Sekiguchi N; Takizawa J; Tsukamoto H; Murayama T; Ando T; Matsuoka H; Hasegawa M; Wada H; Sakai R; Kameoka Y; Tsukamoto N; Choi I; Masaki Y; Shimada K; Fukuhara N; Utsumi T; Uoshima N; Kagami Y; Asano N; Ejima Y; Katayama N; Yamaguchi M
    Hematol Oncol; 2022 Oct; 40(4):667-677. PubMed ID: 35142384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.
    Yamaguchi M; Tobinai K; Oguchi M; Ishizuka N; Kobayashi Y; Isobe Y; Ishizawa K; Maseki N; Itoh K; Usui N; Wasada I; Kinoshita T; Ohshima K; Matsuno Y; Terauchi T; Nawano S; Ishikura S; Kagami Y; Hotta T; Oshimi K
    J Clin Oncol; 2009 Nov; 27(33):5594-600. PubMed ID: 19805668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma.
    Wang YQ; Yang Y; Zhuo HY; Zou LQ; Jiang Y; Jiang M
    Med Oncol; 2015 Feb; 32(2):435. PubMed ID: 25572807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
    Yoon DH; Kim SJ; Jeong SH; Shin DY; Bae SH; Hong J; Park SK; Yhim HY; Yang DH; Lee H; Kang HJ; Lee MH; Eom HS; Kwak JY; Lee JH; Suh C; Kim WS
    Oncotarget; 2016 Dec; 7(51):85584-85591. PubMed ID: 27542213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective analysis of treatment outcomes for extranodal NK/T-cell lymphoma (ENKL), nasal type, stage I-IIE: single institute experience of combined modality treatment for early localized nasal extranodal NK/T-cell lymphoma (ENKL).
    Lee J; Cho SG; Chung SM; Ryu MR; Kim SH; Jang HS; Choi BO
    Ann Hematol; 2013 Mar; 92(3):333-43. PubMed ID: 23180438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Extranodal NK/T-cell lymphoma].
    Suzuki R
    Nihon Rinsho; 2014 Mar; 72(3):524-30. PubMed ID: 24724414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin.
    Yamaguchi M; Suzuki R; Miyazaki K; Amaki J; Takizawa J; Sekiguchi N; Kinoshita S; Tomita N; Wada H; Kobayashi Y; Niitsu N; Ando T; Maeda T; Saito B; Matsuoka H; Sakai R; Kubota N; Masaki Y; Kameoka Y; Asano N; Oguchi M; Katayama N
    Ann Hematol; 2019 Jul; 98(7):1647-1655. PubMed ID: 31001658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of PVD regimen combined with IMRT for early-stage extranodal nasal NK/T-cell lymphoma].
    Zhang Y; Huang YH; Hu YF; Liu QL; Wu T
    Zhonghua Yi Xue Za Zhi; 2017 Jul; 97(26):2047-2049. PubMed ID: 28763877
    [No Abstract]   [Full Text] [Related]  

  • 19. NK-Cell Lymphomas.
    Chihara D; Oki Y
    Cancer Treat Res; 2019; 176():163-184. PubMed ID: 30596218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II prospective study of the "Sandwich" protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma.
    Jiang M; Zhang L; Xie L; Zhang H; Jiang Y; Liu WP; Zhang WY; Tian R; Deng YT; Zhao S; Zou LQ
    Oncotarget; 2017 Jul; 8(30):50155-50163. PubMed ID: 28404973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.